Denali Therapeutics (NASDAQ:DNLI) Shares Down 4.1% Following Insider Selling

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) dropped 4.1% during mid-day trading on Monday following insider selling activity. The company traded as low as $20.25 and last traded at $20.39. Approximately 209,130 shares changed hands during trading, a decline of 56% from the average daily volume of 479,181 shares. The stock had previously closed at $21.26.

Specifically, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company's stock, valued at $2,257,778.16. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Stifel Nicolaus raised shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 target price on the stock in a report on Monday, December 16th. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group increased their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their price target on Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Finally, William Blair assumed coverage on Denali Therapeutics in a research report on Friday. They issued an "outperform" rating for the company. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $40.40.

Denali Therapeutics Stock Performance

The firm's 50-day moving average is $24.46 and its 200 day moving average is $24.89. The firm has a market capitalization of $2.85 billion, a PE ratio of -7.18 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the business posted ($0.72) EPS. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in Denali Therapeutics by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock worth $312,491,000 after purchasing an additional 903,683 shares in the last quarter. FMR LLC grew its holdings in shares of Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company's stock worth $228,128,000 after buying an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Denali Therapeutics by 63.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock worth $109,223,000 after buying an additional 1,451,770 shares in the last quarter. Marshall Wace LLP raised its position in shares of Denali Therapeutics by 12.7% in the second quarter. Marshall Wace LLP now owns 2,418,833 shares of the company's stock valued at $56,165,000 after buying an additional 272,454 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Denali Therapeutics by 6.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company's stock valued at $32,913,000 after buying an additional 84,522 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.